Live Feeds
● LIVE Updated 1d ago · 37 sources tracked

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

AbbVie entered a definitive agreement on June 22 to acquire Apogee Therapeutics for $135.11 per share in cash. The deal provides AbbVie with a pipeline of clinical-stage assets for inflammatory and immunological diseases, including asthma and atopic dermatitis. Both company boards approved the transaction unanimously.

RSS Source map (31)

What changed

New details identify the specific per-share price, key drug candidates, and the expected closing timeframe.

Live updates

  1. AbbVie to Acquire Apogee Therapeutics for $10.9 Billion

    AbbVie entered a definitive agreement on June 22 to acquire Apogee Therapeutics for $135.11 per share in cash. The deal provides AbbVie with a pipeline of clinical-stage assets for inflammatory and immunological diseases, including asthma and atopic dermatitis. Both company boards approved the transaction unanimously.

    What's confirmed:

    • AbbVie will acquire Apogee Therapeutics for $10.9 billion.
    • The acquisition price is $135.11 per share in cash.
    • The boards of both companies unanimously approved the deal.
    • The transaction is expected to close in the third quarter of 2026.
    • The acquisition includes zumilokibart, a late-stage monoclonal antibody targeting IL-13 in atopic dermatitis.
    • AbbVie acquires APG273, a combination program for asthma pairing zumilokibart with APG333.
    • The agreement was announced on June 22.

    Still unconfirmed:

    • The acquisition is intended to offset revenue impact from the Humira patent cliff.
    • This is AbbVie's largest deal in over five years.
    confidence 100%

  2. AbbVie to Acquire Apogee Therapeutics for $10.9 Billion

    AbbVie has reached a deal to acquire Apogee Therapeutics in a transaction valued at $10.9 billion. The acquisition aims to expand AbbVie's immunology portfolio with long-acting drug candidates for inflammatory and immunological conditions. The deal includes prospects for treating eczema.

    What's confirmed:

    • AbbVie is acquiring Apogee Therapeutics for $10.9 billion.
    • The acquisition focuses on long-acting immunology and inflammatory drug candidates.
    • The deal includes assets intended for patients with respiratory, dermatologic, and other related inflammatory conditions.
    • The acquisition includes a prospect for treating eczema.
    • The announcement was made on June 22, 2026.

    Still unconfirmed:

    • JPMorgan describes the acquisition as a solid fit.
    • Ademi LLP is investigating if Apogee Therapeutics public shareholders are receiving a fair price.
    confidence 100%